JP2017501725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501725A5 JP2017501725A5 JP2016542697A JP2016542697A JP2017501725A5 JP 2017501725 A5 JP2017501725 A5 JP 2017501725A5 JP 2016542697 A JP2016542697 A JP 2016542697A JP 2016542697 A JP2016542697 A JP 2016542697A JP 2017501725 A5 JP2017501725 A5 JP 2017501725A5
- Authority
- JP
- Japan
- Prior art keywords
- fcrn antagonist
- region
- pharmaceutical composition
- fcrn
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 43
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 43
- 239000005557 antagonist Substances 0.000 claims 38
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000003814 drug Substances 0.000 claims 11
- 150000001413 amino acids Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 150000004676 glycans Chemical class 0.000 claims 5
- 108010073807 IgG Receptors Proteins 0.000 claims 4
- 102000009490 IgG Receptors Human genes 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 4
- 208000037908 antibody-mediated disorder Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 230000000779 depleting effect Effects 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 239000004606 Fillers/Extenders Substances 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 claims 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000001930 Autoimmune limbic encephalitis Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 102100027217 CD82 antigen Human genes 0.000 claims 1
- 102100035793 CD83 antigen Human genes 0.000 claims 1
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000011038 Cold agglutinin disease Diseases 0.000 claims 1
- 206010009868 Cold type haemolytic anaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010059284 Epidermal necrosis Diseases 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 claims 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 claims 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 claims 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020633 Hyperglobulinaemia Diseases 0.000 claims 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100025574 Leukocyte immunoglobulin-like receptor subfamily A member 5 Human genes 0.000 claims 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 claims 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000017281 Morvan syndrome Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 102000003729 Neprilysin Human genes 0.000 claims 1
- 108090000028 Neprilysin Proteins 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 208000025174 PANDAS Diseases 0.000 claims 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 102100029216 SLAM family member 5 Human genes 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229960001838 canakinumab Drugs 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 201000003278 cryoglobulinemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960002224 eculizumab Drugs 0.000 claims 1
- 229960000284 efalizumab Drugs 0.000 claims 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229960000470 omalizumab Drugs 0.000 claims 1
- 210000004738 parenchymal cell Anatomy 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 229960003824 ustekinumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920547P | 2013-12-24 | 2013-12-24 | |
| US61/920,547 | 2013-12-24 | ||
| PCT/US2014/072087 WO2015100299A1 (en) | 2013-12-24 | 2014-12-23 | Fcrn antagonists and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002272A Division JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501725A JP2017501725A (ja) | 2017-01-19 |
| JP2017501725A5 true JP2017501725A5 (enExample) | 2017-12-14 |
| JP6554473B2 JP6554473B2 (ja) | 2019-07-31 |
Family
ID=52347464
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542697A Active JP6554473B2 (ja) | 2013-12-24 | 2014-12-23 | ＦｃＲｎアンタゴニスト及び使用方法 |
| JP2019002272A Pending JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019002272A Pending JP2019076103A (ja) | 2013-12-24 | 2019-01-10 | ＦｃＲｎアンタゴニスト及び使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10316073B2 (enExample) |
| EP (2) | EP3626738A1 (enExample) |
| JP (2) | JP6554473B2 (enExample) |
| KR (3) | KR20220152546A (enExample) |
| CN (2) | CN106103476B (enExample) |
| AU (1) | AU2014369999B2 (enExample) |
| BR (1) | BR112016014810B1 (enExample) |
| CA (1) | CA2934644C (enExample) |
| DK (1) | DK3087095T3 (enExample) |
| EA (1) | EA035324B1 (enExample) |
| ES (1) | ES2742682T3 (enExample) |
| FI (1) | FIC20230003I1 (enExample) |
| FR (1) | FR23C1004I2 (enExample) |
| HU (2) | HUE046822T2 (enExample) |
| IL (1) | IL246223B (enExample) |
| LT (2) | LT3087095T (enExample) |
| LU (1) | LUC00284I2 (enExample) |
| MX (1) | MX368804B (enExample) |
| NL (1) | NL301203I2 (enExample) |
| NO (1) | NO2022049I1 (enExample) |
| NZ (1) | NZ722055A (enExample) |
| PL (1) | PL3087095T3 (enExample) |
| PT (1) | PT3087095T (enExample) |
| SG (2) | SG11201605203UA (enExample) |
| WO (1) | WO2015100299A1 (enExample) |
| ZA (2) | ZA201604464B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6554473B2 (ja) | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | ＦｃＲｎアンタゴニスト及び使用方法 |
| AU2016230827B2 (en) * | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
| EP3257866A1 (en) * | 2016-06-17 | 2017-12-20 | Academisch Medisch Centrum | Modified anti-tnf antibody and use thereof in the treatment of ibd |
| CA3030099A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| GB201618424D0 (en) * | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| CN110799210A (zh) | 2016-12-02 | 2020-02-14 | 得克萨斯A&M大学系统 | 选择性消耗抗原特异性抗体的融合蛋白 |
| JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ＡｐｏＣ３抗体およびその使用方法 |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| BR112020008514A2 (pt) | 2017-10-31 | 2020-10-20 | Staten Biotechnology B.V. | anticorpos anti-apoc3 e métodos de uso dos mesmos |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| US12202900B2 (en) * | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| EP3823978A4 (en) * | 2018-07-20 | 2022-12-14 | Momenta Pharmaceuticals, Inc. | Fcrn antibody compositions |
| WO2020054979A1 (ko) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물 |
| GB2589049C (en) * | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| JP7565951B2 (ja) | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
| CA3163172A1 (en) | 2020-01-08 | 2021-07-15 | Peter Verheesen | Methods for treating pemphigus disorders |
| WO2021160116A1 (zh) * | 2020-02-10 | 2021-08-19 | 北京拓界生物医药科技有限公司 | 抗FcRn抗体、其抗原结合片段及其医药用途 |
| CN113769058B (zh) * | 2020-06-10 | 2024-09-06 | 上海宝济药业股份有限公司 | 一种药物组合及其应用 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US20240309065A1 (en) | 2021-06-23 | 2024-09-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Short apoc-ii mimetic peptides and methods of use |
| IL314367A (en) | 2022-01-18 | 2024-09-01 | argenx BV | Antibodies to galectin 10 |
| AU2023221552A1 (en) | 2022-02-21 | 2024-09-05 | argenx BV | Methods for treating myositis using fcrn antagonists |
| WO2023198806A1 (en) | 2022-04-13 | 2023-10-19 | Ose Immunotherapeutics | New class of molecules for selective clearance of antibody |
| WO2023215838A1 (en) | 2022-05-05 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Short apolipoprotein e mimetic peptides and methods of use |
| CN119630697A (zh) | 2022-06-15 | 2025-03-14 | 阿根思有限公司 | Ph依赖性hsa结合分子及使用方法 |
| CN115645537A (zh) * | 2022-10-25 | 2023-01-31 | 成都臻拓医药科技有限公司 | FcRn抑制剂在制备抑制自身免疫性疾病复发的药物中的用途 |
| JP2025537777A (ja) * | 2022-11-14 | 2025-11-20 | アルジェニクス ビーブイ | ＦｃＲｎアンタゴニスト分子及びそれらの使用方法 |
| IL322228A (en) | 2023-02-04 | 2025-09-01 | Momenta Pharmaceuticals Inc | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024206214A1 (en) * | 2023-03-24 | 2024-10-03 | Paragon Therapeutics, Inc. | Fc fragments that bind fcrn and methods of use |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025017368A1 (en) | 2023-07-16 | 2025-01-23 | argenx BV | Methods of treating chronic inflammatory demyelinating polyneuropathy |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025099576A1 (en) | 2023-11-06 | 2025-05-15 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating rheumatoid arthritis |
| GB202319605D0 (en) | 2023-12-20 | 2024-01-31 | argenx BV | Monovalent binding molecules and methods of use |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025229224A1 (en) | 2024-05-03 | 2025-11-06 | argenx BV | Monovalent anti-iga binding molecules and methods of use |
| WO2025233684A1 (en) | 2024-05-10 | 2025-11-13 | argenx BV | Subcutaneous formulations, pre-filled syringes and methods of use thereof |
| WO2025233685A1 (en) | 2024-05-10 | 2025-11-13 | argenx BV | Intravenous fcrn antagonist formulations and methods of use thereof |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62153300A (ja) * | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法 |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| ATE238668T1 (de) | 1995-01-17 | 2003-05-15 | Brigham & Womens Hospital | Rezeptorspezifischer transepithelialer transport von immunogenen |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6128119A (en) | 1997-01-10 | 2000-10-03 | Asahi Kogaku Kogyo Kabushiki Kaisha | Beam shaping optical system |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
| US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6992234B2 (en) | 2000-11-06 | 2006-01-31 | The Jackson Laboratory | FcRn-based therapeutics for the treatment of auto-immune disorders |
| CA2467781C (en) | 2000-11-20 | 2014-09-23 | Canadian Blood Services | Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| CA2455365C (en) | 2001-08-03 | 2014-07-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP3945281B2 (ja) | 2002-03-19 | 2007-07-18 | 富士ゼロックス株式会社 | 画像形成装置 |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| JP4459810B2 (ja) | 2002-08-14 | 2010-04-28 | マクロジェニクス，インコーポレーテッド | ＦｃγＲＩＩＢ特異的抗体とその利用法 |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP4773947B2 (ja) | 2003-01-09 | 2011-09-14 | マクロジェニクス，インコーポレーテッド | 細菌細胞及び哺乳動物細胞における抗体発現のための二重発現ベクター系 |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| BRPI0406724A (pt) | 2003-01-13 | 2005-12-20 | Macrogenics Inc | Proteìna de fusão dimérica, métodos de tratar, prevenir ou melhorar um ou mais sintomas de um distúrbio autoimune e um ou mais sintomas de púrpura trombocitopênica idiopática, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, método de produzir recombinantemente o polipeptìdeo, polipeptìdeo isolado, fragmento de qualquer um dos polipeptìdeos, e, molécula de ácido nucleico isolada |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| EP1798864A4 (en) | 2004-09-30 | 2013-07-31 | Brother Ind Ltd | WIRELESS LABEL COMMUNICATION DEVICE, WIRELESS LABEL, WIRELESS COMMUNICATION SYSTEM AND METHOD OF WIRELESS COMMUNICATION |
| WO2006118772A2 (en) | 2005-04-29 | 2006-11-09 | The Jackson Laboratory | Fcrn antibodies and uses thereof |
| EP1896503B1 (en) | 2005-05-31 | 2014-10-29 | Board of Regents, The University of Texas System | IgG1 ANTIBODIES WITH MUTATED Fc PORTION FOR INCREASED BINDING TO FcRn RECEPTOR AND USES TEHEREOF |
| TW200745163A (en) | 2006-02-17 | 2007-12-16 | Syntonix Pharmaceuticals Inc | Peptides that block the binding of IgG to FcRn |
| US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
| BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
| EP2185589B1 (en) * | 2007-06-01 | 2016-01-06 | University of Maryland, Baltimore | Immunoglobulin constant region fc receptor binding agents |
| US8732170B2 (en) | 2007-11-27 | 2014-05-20 | Zettics, Inc. | Method and apparatus for real-time multi-dimensional reporting and analyzing of data on application level activity and other user information on a mobile data network |
| US9260525B2 (en) * | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2009100105A2 (en) * | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| CA3131470A1 (en) | 2008-04-25 | 2009-10-29 | Takeda Pharmaceutical Company Limited | Fc receptor binding proteins |
| WO2010014909A1 (en) * | 2008-08-01 | 2010-02-04 | Syntonix Pharmaceuticals, Inc. | Immunomodulatory peptides |
| EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| KR101808602B1 (ko) * | 2009-10-07 | 2017-12-13 | 마크로제닉스, 인크. | 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법 |
| MX368531B (es) * | 2010-07-28 | 2019-10-07 | Gliknik Inc | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. |
| GB201111291D0 (en) | 2011-06-30 | 2011-08-17 | Agco Int Gmbh | Engine control system |
| US9790280B2 (en) | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| WO2013074598A1 (en) * | 2011-11-18 | 2013-05-23 | Merck Sharp & Dohme Corp. | Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| CN104428416B (zh) | 2012-07-05 | 2019-01-29 | 弗·哈夫曼-拉罗切有限公司 | 表达和分泌系统 |
| GB201302878D0 (en) | 2013-02-19 | 2013-04-03 | Argen X Bv | Modified igG molecules |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| ES2909014T3 (es) | 2013-11-26 | 2022-05-04 | Brigham & Womens Hospital Inc | Composiciones y métodos para modular una respuesta inmunitaria |
| JP6554473B2 (ja) | 2013-12-24 | 2019-07-31 | アルゲン−エックス ビーブイビーエー | ＦｃＲｎアンタゴニスト及び使用方法 |
| US10323066B2 (en) | 2014-09-17 | 2019-06-18 | Affibody Ab | Neonatal Fc receptor binding dimer and methods of use |
| SG10202007232WA (en) | 2015-01-30 | 2020-09-29 | Momenta Pharmaceuticals Inc | Fcrn antibodies and methods of use thereof |
| AU2016230827B2 (en) | 2015-03-09 | 2021-10-28 | argenx BV | Methods of reducing serum levels of fc-containing agents using fcrn antagonists |
| CA3022547A1 (en) | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| US10507234B2 (en) | 2015-07-17 | 2019-12-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens |
| CN106957365B (zh) | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| GB201618424D0 (en) | 2016-11-01 | 2016-12-14 | Argenix Bvba | Treatment of antibody mediated disease |
| KR20200096786A (ko) | 2017-12-08 | 2020-08-13 | 아르제넥스 비브이비에이 | 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도 |
| US12202900B2 (en) | 2018-06-08 | 2025-01-21 | argenx BV | Compositions and methods for treating immune thrombocytopenia |
| US20220298241A1 (en) | 2019-05-17 | 2022-09-22 | Alexion Pharmaceuticals, Inc. | Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases |
| JP7565951B2 (ja) * | 2019-06-07 | 2024-10-11 | アルジェニクス ビーブイ | 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤 |
-
2014
- 2014-12-23 JP JP2016542697A patent/JP6554473B2/ja active Active
- 2014-12-23 NZ NZ722055A patent/NZ722055A/en unknown
- 2014-12-23 BR BR112016014810-0A patent/BR112016014810B1/pt active IP Right Grant
- 2014-12-23 HU HUE14827372A patent/HUE046822T2/hu unknown
- 2014-12-23 AU AU2014369999A patent/AU2014369999B2/en active Active
- 2014-12-23 SG SG11201605203UA patent/SG11201605203UA/en unknown
- 2014-12-23 MX MX2016008399A patent/MX368804B/es active IP Right Grant
- 2014-12-23 PT PT148273725T patent/PT3087095T/pt unknown
- 2014-12-23 KR KR1020227034365A patent/KR20220152546A/ko not_active Ceased
- 2014-12-23 KR KR1020247006088A patent/KR20240033084A/ko not_active Ceased
- 2014-12-23 EA EA201691304A patent/EA035324B1/ru unknown
- 2014-12-23 CA CA2934644A patent/CA2934644C/en active Active
- 2014-12-23 CN CN201480070435.1A patent/CN106103476B/zh active Active
- 2014-12-23 LT LTEP14827372.5T patent/LT3087095T/lt unknown
- 2014-12-23 CN CN202010983097.8A patent/CN112142843B/zh active Active
- 2014-12-23 EP EP19189186.0A patent/EP3626738A1/en active Pending
- 2014-12-23 WO PCT/US2014/072087 patent/WO2015100299A1/en not_active Ceased
- 2014-12-23 KR KR1020167020339A patent/KR102452173B1/ko active Active
- 2014-12-23 DK DK14827372T patent/DK3087095T3/da active
- 2014-12-23 ES ES14827372T patent/ES2742682T3/es active Active
- 2014-12-23 PL PL14827372T patent/PL3087095T3/pl unknown
- 2014-12-23 US US14/580,771 patent/US10316073B2/en active Active
- 2014-12-23 EP EP14827372.5A patent/EP3087095B1/en active Active
- 2014-12-23 SG SG10202009832XA patent/SG10202009832XA/en unknown
-
2016
- 2016-06-14 IL IL246223A patent/IL246223B/en unknown
- 2016-06-30 ZA ZA2016/04464A patent/ZA201604464B/en unknown
-
2017
- 2017-11-22 US US15/821,104 patent/US11505585B2/en active Active
-
2019
- 2019-01-10 JP JP2019002272A patent/JP2019076103A/ja active Pending
-
2022
- 2022-02-15 US US17/672,346 patent/US20220275035A1/en active Pending
- 2022-11-03 NL NL301203C patent/NL301203I2/nl unknown
- 2022-11-09 LU LU00284C patent/LUC00284I2/fr unknown
- 2022-11-15 LT LTPA2022014C patent/LTC3087095I2/lt unknown
- 2022-11-21 HU HUS2200048C patent/HUS2200048I1/hu unknown
- 2022-11-23 NO NO2022049C patent/NO2022049I1/no unknown
-
2023
- 2023-01-12 FR FR23C1004C patent/FR23C1004I2/fr active Active
- 2023-01-19 FI FIC20230003C patent/FIC20230003I1/fi unknown
-
2024
- 2024-12-23 ZA ZA2024/09972A patent/ZA202409972B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501725A5 (enExample) | ||
| JP2022105084A5 (enExample) | ||
| JP2018509413A5 (enExample) | ||
| US12404340B2 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| CN110669135B (zh) | 一种双特异性抗体及其用途 | |
| JP2016527187A5 (enExample) | ||
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| AU2023291783A1 (en) | Fcrn binding molecules and methods of use | |
| JP2011506422A5 (enExample) | ||
| CN111886023B (zh) | 针对tim-3的抗体及其用途 | |
| JP7688805B2 (ja) | 二重特異性抗体 | |
| JPWO2020004490A5 (enExample) | ||
| CN114025797A (zh) | 抗Gal9免疫抑制性结合分子 | |
| WO2016031932A1 (ja) | アルカリ洗浄によるＦｃ領域を有するタンパク質の製造方法 | |
| AU2016404449A1 (en) | Trispecific antibodies against IL-17A, IL-17F and another proinflammatory molecule | |
| JP2021075580A5 (enExample) | ||
| NZ773089B2 (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| NZ773089A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| CN117157323A (zh) | 新型多特异性抗体 | |
| CN116997354A (zh) | 用于诊断和治疗用途的针对lilrb1的单克隆抗体 | |
| CN117820481B (zh) | 新型抗体分子及其制药用途 | |
| NZ734416A (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| JPWO2023242372A5 (enExample) | ||
| RU2023135361A (ru) | Белки, которые связываются с cd80 и/или cd86 и ox40l | |
| HK40009608B (zh) | 针对信号调控蛋白α的抗体和使用方法 |